- Home
- RPRX vs SF Comparison
RPRX vs SF Comparison
Compare RPRX & SF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- SF
- Stock Information
- Founded
- RPRX 1996
- SF 1890
- Country
- RPRX United States
- SF United States
- Employees
- RPRX N/A
- SF N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- SF Investment Bankers/Brokers/Service
- Sector
- RPRX Health Care
- SF Finance
- Exchange
- RPRX Nasdaq
- SF Nasdaq
- Market Cap
- RPRX 14.0B
- SF 12.0B
- IPO Year
- RPRX 2020
- SF N/A
- Fundamental
- Price
- RPRX $33.88
- SF $103.93
- Analyst Decision
- RPRX Strong Buy
- SF Hold
- Analyst Count
- RPRX 5
- SF 8
- Target Price
- RPRX $41.60
- SF $117.71
- AVG Volume (30 Days)
- RPRX 4.6M
- SF 715.2K
- Earning Date
- RPRX 02-11-2025
- SF 01-29-2025
- Dividend Yield
- RPRX 2.60%
- SF 1.73%
- EPS Growth
- RPRX N/A
- SF 46.03
- EPS
- RPRX 1.91
- SF 6.25
- Revenue
- RPRX $2,263,576,000.00
- SF $4,970,320,000.00
- Revenue This Year
- RPRX $29.18
- SF $15.10
- Revenue Next Year
- RPRX $9.99
- SF $9.19
- P/E Ratio
- RPRX $17.69
- SF $17.02
- Revenue Growth
- RPRX N/A
- SF 14.95
- 52 Week Low
- RPRX $24.05
- SF $72.78
- 52 Week High
- RPRX $34.16
- SF $120.64
- Technical
- Relative Strength Index (RSI)
- RPRX 80.55
- SF 36.22
- Support Level
- RPRX $32.28
- SF $102.16
- Resistance Level
- RPRX $34.20
- SF $111.62
- Average True Range (ATR)
- RPRX 0.71
- SF 2.75
- MACD
- RPRX 0.02
- SF -0.95
- Stochastic Oscillator
- RPRX 89.40
- SF 13.38
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About SF Stifel Financial Corporation
Stifel Financial is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 60% of the company's net revenue is derived from its global wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.